Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMLI Conditioning for Allo-HSCT in MDS/AML
NCT06598969Phase 2Not yet recruiting
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Progression-free survival at 2 years. Planned start Dec 2024; status: not yet recruiting.
02
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06598969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598969.